Off-Target Biology and Genomics Scientist - Gene Therapy

Eurofins USA PSS Insourcing Solutions•Boston, MA

1d•Onsite

About The Position

Eurofins Professional Scientific Services (PSS) is seeking a highly motivated Off-Target Biology and Genomics Scientist to join our team. This role will focus on leading and executing genomic safety assessment packages for gene editing therapeutics. You will be responsible for off-target discovery, verification/validation, and genomic integrity characterization. This position offers the opportunity to break into the biopharmaceutical industry and grow your career with a supportive team and competitive benefits. Eurofins Scientific is a global leader in life sciences, providing a wide range of analytical testing services to ensure the safety, authenticity, and accuracy of products across various industries.

Requirements

B.S. in genomics, molecular biology, biochemistry, or a related field with 5+ years of industry experience in off-target assessment and/or genomic safety evaluation for gene editing therapeutics.
M.S. in genomics, molecular biology, biochemistry, or a related field with 3-7 years of industry experience in off-target assessment and/or genomic safety evaluation for gene editing therapeutics.
Ph.D. in genomics, molecular biology, biochemistry or related field with 2-4 years of industry experience in off-target assessment and/or genomic safety evaluation for gene editing therapeutics.
Proficiency with CRISPR-based genome editing and familiarity with a broad range of off-target discovery platforms.
Experience with next-generation sequencing workflows and data interpretation.
Familiarity with emerging modalities such as base editing and prime editing, and their associated genotoxicity considerations.
Strong track record of scientific problem-solving.
Excellent written and verbal communication skills; ability to present complex data to cross-functional teams.
Ability to work independently and as a part of a team, self-motivation, adaptability, and a positive attitude.

Nice To Haves

Experience with assay development.
Experience with optical genome mapping (Bionano platform).
Familiarity with regulatory expectations around genomic safety packages for IND/BLA submissions.
Experience with human diversity-dependent off-target discovery approaches (e.g., ONE-seq).

Responsibilities

Lead and execute genomic safety assessment packages for gene editing therapeutics, spanning off-target discovery, verification/validation, and genomic integrity characterization.
Apply and evaluate a range of off-target discovery approaches, including in silico tools (CALITAS, CRISPRMe, CasOFFinder), biochemical methods (SITE-seq, CIRCLE-seq, CHANGE-seq, Digenome-seq), and cell-based assays (GUIDE-seq, INDUCE-seq).
Drive off-target verification and validation using amplicon-based sequencing approaches such as AmpSeq, rhAmpSeq, and hybrid capture sequencing.
Characterize genomic integrity using orthogonal methods including karyotyping, optical genome mapping, and WGS.
Assess genotoxicity potential of next-generation genome engineering modalities (base editors, prime editors) using modality-appropriate off-target assessment strategies.
Contribute to or lead novel assay development efforts to interrogate emerging genome editing modalities (Gen 5+).
Integrate biodistribution data to guide tissue selection for off-target verification studies.